ECHO 5: T1D and Neuropathy

Registration for this live ECHO program has capped. Please register for the on-demand session here.

Each ECHO will have a live and on-demand component; please note that participation in the live event is limited to 25 persons per event and that those who participate in the live ECHO may receive credit from the live event but are not eligible to also receive credit for the on-demand webinar. 

Endocrine Society is pleased to participate in Project ECHO: Type 1 Diabetes Care and Management. The fourth ECHO in this series, Type 1 Diabetes and Neuropathy, will feature Lucia Novak, MSN, ANP-BC, BC-ADM as she discusses managing and preventing neuropathy in patients with T1D. The live, interactive ECHO will take place on Thursday, January 28, 2021 at 4pm PT // 5pm MT //  6pm CT // 7pm ET.

The CME evaluation will be available for the live course until February 12th, at which point the enduring material will become available. Those who register for the live event but do not attend will have their registration transferred to the on-demand webinar.

Please note that to participate in this ECHO, you must complete registration for the Project ECHO program.

About this ECHO

By the end of this ECHO, participants will be able to:

  • Identify the clinical manifestations of peripheral neuropathy and cardiac autonomic neuropathy
  • Apply current screening recommendations to ensure patients receive timely care
  • Review the components of a comprehensive foot exam.

Supporting articles for this session:

Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care. 2005 Jun;28(6):1480-1. doi: 10.2337/diacare.28.6.1480. PMID: 15920071.

Freeman R. Not all neuropathy in diabetes is of diabetic etiology: differential diagnosis of diabetic neuropathy. Curr Diab Rep. 2009 Dec;9(6):423-31. doi: 10.1007/s11892-009-0069-7. PMID: 19954686.

Space is limited to 25 participants on the live webinar. Register today!

Unable to attend the live event? Register for the on-demand session here!

Target Audience

This program will be of substantial interest to endocrinologists and fellows caring for individuals with, or at risk for developing, type 1 diabetes and associated diseases. Additionally, this program may be of interest to primary care professionals, care teams, and advance practice professionals who treat patients with type 1 diabetes.

Learning Objectives

By the end of this ECHO, participants will be able to:

  • Identify the clinical manifestations of peripheral neuropathy and cardiac autonomic neuropathy
  • Apply current screening recommendations to ensure patients receive timely care
  • Review the components of a comprehensive foot exam.

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Topic Area: 
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
12/28/2020
Course expires: 
02/02/2021
Rating: 
0

FACULTY

Lucia Novak, MSN, ANP-BC, BC-ADM
Capital Diabetes & Endocrine Associates

PEER-REVIEWER

Lorena Alarcon-Casas Wright, MD, FACE
Univeristy of Washington School of Medicine

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships: 
Lucia Novak, MSN, ANP-BC, BC-ADM:  Abbott Diabetes Care, AstraZeneca, Janssen, Novo Nordisk, Xeris - Speaker; Abbott Diabetes Care, Novo Nordisk, Xeris, Sanofi - Consultant; Abbott Diabetes Care, Janssen, Novo Nordisk, Xeris, Sanofi - Advisor.

Disclosure information for guest speakers is included in their individual recorded presentations.

The following peer reviewer reported no relevant financial relationships: 
Lorena Alarcon-Casas Wright, MD, FACE

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:
The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE:

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT:

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT:

This educational activity is supported by independent medical educational grants from Abbott Diabetes Care, Inc., Dexcom, Inc., Helmsley Charitable Trust, Insulet Corporation, Lilly USA LLC, Medtronic Diabetes, and Novo Nordisk Inc., Tandem Diabetes Care. 

Accreditation Statement

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.

The Endocrine Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit can be claimed for the live webinar 1/29/2021 at 7:00pm ET through 2/12/2021 at 11:59pm ET.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
There are no more spaces available for this course.

Each ECHO will have a live and on-demand component; please note that participation in the live event is limited to 25 persons per event and that those who participate in the live ECHO may receive credit from the live event but are not eligible to receive credit for the on-demand webinar. 

Thank you for your interest in the Neuropathy in Type 1 Diabetes ECHO with Lucia Novak, MSN, ANP-BC, BC-ADM. Please click Register below to complete a short pre-survey and gain access to the journal article and case submission portal. 

To access the case submission portal and Zoom information:

  • Click 'Start'
  • Complete the short pre-survey
  • Click into the case submission portal and upload your case and questions
  • Click into Zoom information to get instructions for access the webinar.